Condition: Cytomegalovirus Infections · Kidney Transplant Infection · Pancreas Transplant · Sponsor: University of Wisconsin, Madison
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
This description comes directly from the study's public registry record.
Sandesh Parajuli, MBBS · (608) 262-2122 · sparajuli@medicine.wisc.edu
Always discuss trial participation with your own doctor first.
| UW Hospital and Clinics | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06407232